AU2014251093B2 - Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere - Google Patents

Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere Download PDF

Info

Publication number
AU2014251093B2
AU2014251093B2 AU2014251093A AU2014251093A AU2014251093B2 AU 2014251093 B2 AU2014251093 B2 AU 2014251093B2 AU 2014251093 A AU2014251093 A AU 2014251093A AU 2014251093 A AU2014251093 A AU 2014251093A AU 2014251093 B2 AU2014251093 B2 AU 2014251093B2
Authority
AU
Australia
Prior art keywords
telomerase
amount
thio
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014251093A
Other languages
English (en)
Other versions
AU2014251093A1 (en
Inventor
Sergei M. Gryaznov
Jerry W. Shay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, The University of Texas at Austin filed Critical The University of Texas System
Publication of AU2014251093A1 publication Critical patent/AU2014251093A1/en
Application granted granted Critical
Publication of AU2014251093B2 publication Critical patent/AU2014251093B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
AU2014251093A 2013-04-08 2014-04-08 Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere Ceased AU2014251093B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361809575P 2013-04-08 2013-04-08
US61/809,575 2013-04-08
PCT/US2014/033330 WO2014168947A2 (en) 2013-04-08 2014-04-08 Telomerase mediated telomere altering compounds

Publications (2)

Publication Number Publication Date
AU2014251093A1 AU2014251093A1 (en) 2015-10-15
AU2014251093B2 true AU2014251093B2 (en) 2017-06-15

Family

ID=50819958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014251093A Ceased AU2014251093B2 (en) 2013-04-08 2014-04-08 Mercaptopurine ribonucleoside analogues for altering telomerase mediated telomere

Country Status (17)

Country Link
US (1) US10463685B2 (enExample)
EP (2) EP3682888B1 (enExample)
JP (1) JP6525956B2 (enExample)
KR (1) KR20150143587A (enExample)
CN (2) CN110339203A (enExample)
AU (1) AU2014251093B2 (enExample)
BR (1) BR112015025206A2 (enExample)
CA (1) CA2907924C (enExample)
ES (1) ES3038057T3 (enExample)
HK (1) HK1219418A1 (enExample)
HU (1) HUE072426T2 (enExample)
MX (1) MX387008B (enExample)
NZ (1) NZ713498A (enExample)
PL (1) PL3682888T3 (enExample)
RU (1) RU2713555C2 (enExample)
SG (2) SG10202002556QA (enExample)
WO (1) WO2014168947A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180036331A1 (en) * 2016-03-24 2018-02-08 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3463370A4 (en) * 2016-05-27 2020-04-08 The Board of Regents of The University of Texas System 6-THIO-2'-DEOXYGUANOSINE (6-THIO-DG) RESULTS IN TELOMERASE-DEPENDENT TELOMER DYS FUNCTION AND CELL DEATH IN THERAPY-RESISTANT CANCER CELL
US20210023107A1 (en) * 2018-03-22 2021-01-28 The Board Of Regents Of The University Of Texas System USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS
AU2019208197B2 (en) 2018-07-31 2025-05-29 Howmedica Osteonics Corp. Fixation devices and prostheses for soft tissue connection to the same
CA3115712A1 (en) * 2018-10-17 2020-04-23 Xibin Liao 6-mercaptopurine nucleoside analogues
USD1046142S1 (en) 2019-07-24 2024-10-08 Howmedica Osteonics Corp. Proximal tibial prosthesis
CN112898292A (zh) 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
FI4117667T3 (fi) 2020-03-13 2025-02-10 Univ Texas Syöpien jaksottainen hoito käyttäen 6-tio-dg- ja tarkistuspisteen inhibiittoreita
CN120981470A (zh) * 2023-03-14 2025-11-18 浙江华海药业股份有限公司 一类核苷类似物及其应用
CN121002041A (zh) * 2023-03-14 2025-11-21 浙江华海药业股份有限公司 一类靶向端粒酶的核苷类似物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444071C (en) 1991-02-08 2008-10-07 Wellstat Therapeutics Corporation Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
EP1879657A2 (en) 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
CN101220071B (zh) * 2008-01-17 2011-04-06 南京长澳医药科技有限公司 稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57209226A (en) * 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US20100323979A1 (en) * 2009-06-16 2010-12-23 Weis-Amon Angelika B Methods and compositions for inhibiting proliferation of aneuploid cells

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ACTON E M ET AL, JOURNAL OF MEDICINAL CHEMISTRY, (1979), vol. 22, no. 5, pages 518 - 525 *
FUKUOKA F ET AL, "RELATION BETWEEN ANTITUMOR ACTIVITY AND CHEMICAL STRUCTURE IN SOME DERIVATIVES OF 2-AMINO-6-PURINETHIOL", GANN, JAPANESE CANCER ASSOCIATION, TOKYO, JP, (19690401), vol. 60, no. 2, ISSN 0016-450X, pages 187 - 197 *
GAGLIANO R G ET AL, CANCER CLINICAL TRIALS (1981), vol. 4, no. 4,, pages 401 - 406 *
LEPAGE ET AL, "Manipulation of DNA synthesis in normal and neoplastic tissues with drugs", ADVANCES IN ENZYME REGULATION, PERGAMON PRESS, OXFORD, GB, vol. 12, (1974), pages 373 - 381, (19740101) *
LEPAGE G A ET AL, "PHARMACOLOGY AND TOXICOLOGY OF ALPHA-2 DEOXY THIO GUANOSINE IN CANCER PATIENTS", CANCER TREATMENT REPORTS, US GOV. PRINT. OFF, US, (19790101), vol. 63, no. 1, ISSN 0361-5960, pages 53 - 57 *
SUSAN W TENDIAN ET AL, "Interaction of Deoxyguanosine Nucleotide Analogs with Human Telomerase 1", MOLECULAR PHARMACOLOGY, (19991220), vol. 57, pages 695 - 699 *
VELLARKAD N. VISWANADHAN ET AL, JOURNAL OF MEDICINAL CHEMISTRY, (1991), vol. 34, no. 2, pages 526 - 532 *
XUPING WU ET AL, BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR CELL RESEARCH (2012), vol. 1823, no. 12, pages 2130 - 2135 *

Also Published As

Publication number Publication date
CA2907924A1 (en) 2014-10-16
JP2016516773A (ja) 2016-06-09
ES3038057T3 (en) 2025-10-09
US10463685B2 (en) 2019-11-05
WO2014168947A9 (en) 2014-12-31
NZ732228A (en) 2020-11-27
WO2014168947A3 (en) 2015-02-19
JP6525956B2 (ja) 2019-06-05
HK1219418A1 (zh) 2017-04-07
EP3682888B1 (en) 2025-06-11
PL3682888T3 (pl) 2025-09-22
WO2014168947A2 (en) 2014-10-16
SG10202002556QA (en) 2020-04-29
US20140303239A1 (en) 2014-10-09
MX2015014159A (es) 2016-06-21
KR20150143587A (ko) 2015-12-23
RU2713555C2 (ru) 2020-02-05
RU2015147555A (ru) 2017-05-15
CN105338987A (zh) 2016-02-17
CA2907924C (en) 2022-10-25
EP3682888A1 (en) 2020-07-22
HUE072426T2 (hu) 2025-11-28
SG11201508336TA (en) 2015-11-27
AU2014251093A1 (en) 2015-10-15
MX387008B (es) 2025-03-19
BR112015025206A2 (pt) 2017-07-18
CN110339203A (zh) 2019-10-18
EP2983675A2 (en) 2016-02-17
NZ713498A (en) 2017-07-28

Similar Documents

Publication Publication Date Title
CA2907924C (en) Telomerase mediated telomere altering compounds
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
JP7071299B2 (ja) ５’リン酸オリゴヌクレオチドの構造および使用
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
KR20140020900A (ko) Ｍｉｒ―34의 합성 모방체
JP2013534424A (ja) 二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物
CN104884090A (zh) 细胞凋亡诱导剂
CN116940324A (zh) 脂质纳米颗粒球形核酸
EP2606909B1 (en) Method and composition for treating, preventing and diagnosing cancer containing cancer stem cells or derived therefrom
US20190365905A1 (en) PHOSPHOROTHIOATE-CONJUGATED miRNAs AND METHODS OF USING THE SAME
NZ732228B2 (en) Telomerase mediated telomere altering compounds
US20250136633A1 (en) Telomere-targeting phosphatidyl-thio conjugates
US20240115594A1 (en) Dinucleotides and their use in treating cancer
WO2017065563A1 (ko) Rna 올리고뉴클레오티드를 포함하는 암 치료용 약학 조성물
WO2020218494A1 (ja) ｍｉＲ３０２核酸改変体
US9617538B2 (en) Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
US10814010B2 (en) FOXC2 inhibitor and methods of use thereof
CN113930423A (zh) 保护心肌细胞免受应激损伤的saRNA及其应用
WO2026057029A1 (zh) 一种dsRNA、其应用及制备方法
WO2024263791A1 (en) Antisense oligonucleotides targeting mir-34a-5p and methods of use thereof
CN119592565A (zh) 调控pkm基因选择性剪接的反义寡核苷酸及其应用
WO2017213851A1 (en) Inhibitory rna-based therapeutics targeting anln for cancer treatment
RS52904B (sr) Mikrornk (mirnk) mir-21 za dijagnozu i terapeutske svrhe

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired